PolyNovo updates on US trial and PMA submission
The update covers the NovoSorb BTM RCT and pre-market approval process.
See the latest news and media coverage for PolyNovo. We track all announcements, press releases, and industry mentions in real time, all in one place.
Developer of synthetic skin substitutes
polynovo.comLast updated
In short: PolyNovo ousted its CEO and saw its Chair resign following reported internal conflicts while reporting a 26% increase in first-half sales.
The update covers the NovoSorb BTM RCT and pre-market approval process.
The milestone abstract covers the CP-003 multicenter IDE RCT sponsored by BARDA.
She assumes the role effective 1 June 2026 with over 20 years in biotech R&D, innovation, and commercialization.
Appointment effective 1 April 2026. She brings extensive experience in healthcare, life sciences, and governance from CSL Limited.
An announcement from Polynovo ( (AU:PNV) ) is now available.
Shares of PolyNovo dropped 9.2% to A$1.14, their lowest level since early November 2023. The leadership change follows articles in The Australian last week, which...
Thank you for standing by, and welcome to the PolyNovo First Half FY '26 Results Webcast. [Operator Instructions] I'd now like to hand the conference...
The news: Medical devices group PolyNovo has seen a 26% jump in first-half sales, according to unaudited trading results released this morning. The numbers: First-half...
Track PolyNovo and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Discover what's making headlines across other trending companies.